Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹1,112Cr
Rev Gr TTM
Revenue Growth TTM
10.48%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

GPTHEALTH
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | | 16.6 | | 3.9 | 3.5 | 1.7 | -2.1 | 5.8 | 2.0 | 9.5 | 12.5 | 17.6 |
| 73 | 77 | 83 | 76 | 76 | 80 | 82 | 81 | 81 | 90 | 96 | 99 |
Operating Profit Operating ProfitCr |
| 24.5 | 19.8 | 22.8 | 21.7 | 23.3 | 18.4 | 22.2 | 20.8 | 20.4 | 16.2 | 19.1 | 17.2 |
Other Income Other IncomeCr | 2 | 1 | 1 | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 1 | 1 |
Interest Expense Interest ExpenseCr | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
Depreciation DepreciationCr | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 7 | 7 |
| 19 | 14 | 19 | 16 | 18 | 15 | 21 | 18 | 16 | 11 | 15 | 13 |
| 9 | 4 | 6 | 5 | 6 | 5 | 6 | 5 | 3 | 3 | 4 | 3 |
|
Growth YoY PAT Growth YoY% | | 30.1 | | 37.4 | 23.8 | -0.2 | 9.8 | 6.8 | 0.6 | -22.9 | -28.5 | -23.5 |
| 10.8 | 10.4 | 12.5 | 11.9 | 12.9 | 10.2 | 14.0 | 12.0 | 12.7 | 7.2 | 8.9 | 7.8 |
| 1.3 | 1.3 | 1.7 | 1.4 | 1.6 | 1.2 | 1.8 | 1.5 | 1.6 | 0.9 | 1.3 | 1.1 |
| Financial Year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 14.6 | 39.0 | 7.0 | 10.8 | 1.7 | 9.9 |
| 176 | 194 | 264 | 287 | 312 | 324 | 366 |
Operating Profit Operating ProfitCr |
| 16.9 | 20.2 | 21.9 | 20.6 | 21.9 | 20.5 | 18.2 |
Other Income Other IncomeCr | 4 | 6 | 5 | 6 | 5 | 8 | 6 |
Interest Expense Interest ExpenseCr | 14 | 14 | 11 | 9 | 7 | 3 | 7 |
Depreciation DepreciationCr | 11 | 12 | 14 | 15 | 18 | 19 | 25 |
| 15 | 29 | 54 | 56 | 68 | 69 | 55 |
| 4 | 8 | 12 | 17 | 20 | 19 | 15 |
|
| | 92.5 | 97.5 | -6.4 | 22.5 | 4.5 | -18.8 |
| 5.2 | 8.7 | 12.3 | 10.8 | 11.9 | 12.3 | 9.1 |
| 4.1 | 7.9 | 5.2 | 4.9 | 6.0 | 6.1 | 4.9 |
| Financial Year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 18 | 18 | 80 | 80 | 82 | 82 | 82 |
| 69 | 76 | 78 | 85 | 136 | 166 | 172 |
Current Liabilities Current LiabilitiesCr | 65 | 60 | 68 | 82 | 77 | 74 | 85 |
Non Current Liabilities Non Current LiabilitiesCr | 117 | 123 | 97 | 80 | 50 | 62 | 125 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 63 | 86 | 86 | 81 | 80 | 79 | 87 |
Non Current Assets Non Current AssetsCr | 246 | 231 | 238 | 245 | 265 | 305 | 376 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 41 | 43 | 66 | 66 | 69 | 67 |
Investing Cash Flow Investing Cash FlowCr | -54 | -16 | -5 | 5 | -25 | -33 |
Financing Cash Flow Financing Cash FlowCr | 12 | -22 | -57 | -73 | -49 | -35 |
|
Free Cash Flow Free Cash FlowCr | -5 | 38 | 59 | 58 | 50 | 18 |
| 378.4 | 203.8 | 158.4 | 170.1 | 144.0 | 135.0 |
CFO To EBITDA CFO To EBITDA% | 115.8 | 87.8 | 89.4 | 89.3 | 78.3 | 80.9 |
| Financial Year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 0 | 0 | 1,448 | 1,204 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 0.0 | 30.3 | 24.1 |
Price To Sales Price To Sales | 0.0 | 0.0 | 0.0 | 0.0 | 3.6 | 3.0 |
Price To Book Price To Book | 0.0 | 0.0 | 0.0 | 0.0 | 6.6 | 4.9 |
| 3.0 | 2.1 | 1.3 | 1.0 | 16.7 | 14.8 |
Profitability Ratios Profitability Ratios |
| 81.9 | 76.4 | 74.1 | 79.0 | 79.3 | 80.6 |
| 16.9 | 20.2 | 21.9 | 20.6 | 21.9 | 20.5 |
| 5.2 | 8.7 | 12.3 | 10.8 | 11.9 | 12.3 |
| 15.0 | 21.2 | 25.1 | 26.3 | 30.2 | 25.7 |
| 12.6 | 22.5 | 26.3 | 23.6 | 21.9 | 20.1 |
| 3.5 | 6.7 | 12.9 | 11.9 | 13.8 | 13.0 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
**GPT Healthcare Limited**, operating under the **ILS Hospitals** brand, is a well-established corporate healthcare provider focused exclusively on Eastern India. Founded in July 2000 in Salt Lake, Kolkata, the company has grown into a trusted network of mid-sized, community-centric tertiary care hospitals. Listed on the BSE and NSE (symbol: GPTHEALTH), GPT Healthcare combines clinical excellence, operational efficiency, and technology-driven care to serve the rising demand for quality healthcare in underpenetrated urban markets.
---
### **Current Network & Capacity (as of Nov 2025)**
The company operates **five multi-specialty hospitals** with a total of **719 beds** across West Bengal, Tripura, and Chhattisgarh:
| Location | Beds | Key Features |
|---------------|------|-------------|
| **Salt Lake** (Kolkata) | 85 | Robotic surgery excellence, 700+ robotic procedures, ARPOB: ₹41,062, Occupancy: 62% |
| **Dum Dum** (Kolkata) | 155 | Highest ARPOB (₹41,183–₹42,684), 69–78% occupancy, renal transplants, EBITDA breakeven in 10 months |
| **Howrah** (Kolkata) | 116 | ARPOB: ₹34,900–₹35,600, robotic knee surgeries (34 performed), rapid EBITDA breakeven (8 months), 45–58% occupancy |
| **Agartala** (Tripura) | 205 | Largest corporate hospital in Tripura, NABH/NABL accredited, radiation oncology launched, 70%+ target occupancy |
| **Raipur** (Chhattisgarh) | 158 | Commissioned Apr 2025; ARPOB ~₹40,000, 7–10% occupancy (ramping up), EBITDA breakeven expected in 12–15 months |
---
### **Financial & Operational Highlights (H1 FY26)**
- **Total Income**: ₹228.92 crore
- **EBITDA Margin**: 18.79% (vs. 22.1% in FY25)
- **Average Revenue Per Occupied Bed (ARPOB)**: ₹38,376 (up from ₹37,180 in FY25)
- **Average Length of Stay (ALOS)**: 3.49 days (vs. 3.54 days in FY25)
- **Bed Occupancy**: 44.7% (impacted by new Raipur launch)
- **ROCE**: 11.7% | **ROE**: 7.4%
- **Dividend Declared**: ₹1 per share
- **Revenue Source**: 94–96% from cash and insurance (strong cash conversion)
- **CFO-to-EBITDA**: ~80% (industry-leading)
---
### **Clinical Excellence & Service Expansion**
- **Robotic Surgery**: Over **700 robotic surgeries** completed across Salt Lake and Howrah (focus on orthopedics, bariatrics, general surgery). Howrah has performed **34 robotic knee surgeries**.
- **Renal Transplants**: Over **141 surgeries in FY25**, expanded to Raipur hospital.
- **Oncology**:
- Radiation oncology launched at **Agartala** (only cancer care hospital in Tripura).
- **CBCC (U.S.) partnership** for LINAC-based services in Agartala (11% revenue share).
- Chemotherapy, oncology surgeries, and upcoming **liver transplants** in Raipur.
- **Advanced Diagnostics**: 3 Tesla MRI, Dual Source CT, Cardiac Cath Lab across multiple facilities.
- **Cardiology**: Strengthening Dum Dum with top specialist recruitment; full-fledged unit planned.
---
### **Strategic Growth & Expansion Plans**
- **1,000-Bed Vision**: Targeting **1,000 beds within 2–3 years** (from 719 in Nov 2025), primarily via greenfield hospitals in Tier I and Tier II cities.
- **Upcoming Expansion**:
- **Jamshedpur, Jharkhand**: 150-bed hospital under MoU; investment of ₹65–74 crore; expected operational by **Q3 FY27**.
- **Ranchi (Jharkhand)**: Lease signed; development underway.
- Future targets: **Varanasi, Cuttack, Assam, Odisha**.
- **Hospital Model**: Right-sized (150–200 beds), asset-light (e.g., Raipur on lease), low per-bed capex (~₹3.6M per bed).
---
### **Technology & Digital Initiatives**
- **Hospital Management Information System (HMIS)**: Digital records, real-time reporting, WhatsApp/email delivery, appointment booking.
- **Mobile App (ILS-MyHealth)**: Scheduled Q4 FY24 launch; features include e-consultations, medical records access, and hospital info.
- **Backend Custom App**: Streamlines internal operations and improves efficiency.
---
### **Accreditations & Reputation**
- All five hospitals are **NABH and NABL accredited**.
- Strong community presence as **trusted "neighbourhood hospitals"** in high-density urban micro-markets.
- Positioned near major transport hubs (rail, airport) for enhanced accessibility.
- Clinical research participation (e.g., BEMAKI trial on acute kidney injury at Dum Dum).